Celularity Inc
celularity.comWhat Do They Do?
Sells placental-derived tissue products for soft-tissue repair and surgery, and develops cellular therapies for physicians treating patients with age-related and other diseases.
10-K for FY2025, filed Apr 30, 2026We also develop and market commercial-stage, off-the-shelf placental-derived biomaterial products, including allografts and connective…View ↗
Specifically, we are developing a differentiated portfolio of off-the-shelf, placental-derived allogeneic cellular therapies and advanced…View ↗
Our Celularity IMPACT platform capitalizes on our integrated processes and the unique biologic characteristics of placental-derived…View ↗
How Do They Make Money?
Celularity sells placental-derived tissue products in individual transactions. Expectant parents pay collection and processing fees after processing and storage upfront or in installments; license agreements may pay milestones, while distributor sales are invoiced after purchase orders.
10-K for FY2025, filed Apr 30, 2026The Company recognizes revenue when control of the products is transferred to its customers in an amount that reflects the consideration it…View ↗
The Company separately recognizes revenues for services to expectant parents who contract with the Company to collect, process and store…View ↗
For all plans (annual, lifetime, 18 years and 25 years), the storage fee is paid at the beginning of the storage period (prepaid plans).…View ↗
At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones…View ↗
While the Company’s direct sales of degenerative disease products are included in product sales, sales through the Company’s network of…View ↗
-
10-K for FY2025, filed Apr 30, 2026
FY2025 revenue by product or service ↗
$26.6M
-
10-K for FY2025, filed Apr 30, 2026
$26.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Apr 30, 2026 |
50%
FY2022: 21%
|
Product, FY2025
$13.2M Sources
|
Sold outright |
|
Service
Mix
10-K for FY2025, filed Apr 30, 2026 |
20%
FY2022: 31%
|
Service, FY2025
$5.4M Sources
|
Mix |
|
License Royalty and Other
Licensed
10-K for FY2025, filed Apr 30, 2026 |
30%
FY2022: 48%
|
License Royalty and Other, FY2025
$7.9M Sources
|
Licensed |
Who Are Their Customers?
Biomaterial products are sold directly and through distribution partners. Expectant parents contract for collection, processing and storage services, while third parties can use contract manufacturing and development services.
10-K for FY2025, filed Apr 30, 2026Growing our existing commercial business and deepening the pipeline of placentally derived biomaterial products. We intend to grow our…View ↗
While the Company’s direct sales of degenerative disease products are included in product sales, sales through the Company’s network of…View ↗
The Company separately recognizes revenues for services to expectant parents who contract with the Company to collect, process and store…View ↗
In addition to our cell therapy candidates, and commercial-stage biomaterial products, we actively pursue revenue-generating opportunities…View ↗
10-K for FY2025, filed Apr 30, 2026
The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking…View ↗
Do Revenues Turn Into Profits?
No. It lost $91.7M in FY2025.
10-K for FY2025, filed Apr 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Oct 20, 2026
$706KView ↗
- ▲ Now profitable
- vs −$24.5M in Q2 FY2025
10-Q for Q2 FY2026, filed Oct 20, 2026
Open tableView ↗
-
Sep 11, 2026
Regained compliance with two Nasdaq listing requirements
The periodic-report filing requirement remained unresolved.
Sources
8-K, filed Sep 14, 2026
On September 11, 2026, Celularity Inc. (“Celularity”) received written notifications from the Listing Qualifications Staff of The Nasdaq…View ↗
-
Jul 29, 2026
Received notice of a Nasdaq bid-price deficiency
The company had until January 19, 2027, to regain compliance.
Sources
8-K, filed Jul 29, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until January 19, 2027, to regain…View ↗
-
Jun 12, 2026
Received notice of a Nasdaq market-value deficiency
The company had until December 7, 2026, to regain compliance.
Sources
8-K, filed Jun 12, 2026
On June 9, 2026, Celularity Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”)…View ↗
Growing. Revenue grew 24% in 4 years, from $21.3M in FY2021 to $26.6M in FY2025, about 6% a year.
Broader marketed biomaterials range
The older report described Biovance and Interfyl as the main biomaterials; the latest report lists additional marketed products, including CentaFlex and Rebound.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 30, 2026We are a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived…View ↗
Interfyl®, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate…View ↗
CentaFlex®, a decellularized human placental matrix allograft derived from human umbilical cord designed for use as a surgical covering…View ↗
ReboundTM, a full thickness, placental derived extracellular matrix that contain amnion and chorion for use as a wound covering or barrier…View ↗
Longevity-centered therapy focus
The older report described therapies across cancer, infectious and degenerative diseases; the latest report emphasizes longevity-focused programs for age-related disease.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 30, 2026We are a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived…View ↗
Who Do They Compete With?
Competes with Fate Therapeutics, Century Therapeutics, Nkarta, Artiva Biotherapeutics, Wugen, Shoreline Biosciences, Mesoblast, Longeveron, Allogene Therapeutics, Atara Biotherapeutics, Adaptimmune Therapeutics, Celyad, CRISPR Therapeutics, Intellia Therapeutics, Gilead Sciences, Poseida Therapeutics, Precision Biosciences, Sangamo Therapeutics, Sana Biotechnology, and Caribou Bio
10-K for FY2025, filed Apr 30, 2026allogeneic NK cellular therapies: Fate Therapeutics Inc., Century Therapeutics, Inc., Nkarta, Inc., Artiva Biotherapeutics, Wugen, and…View ↗
Loading...
